John Gunn - Dodge & Cox
Holding/activity history for Neurocrine Biosciences Inc. (NBIX)
| Period | Shares | % of Portfolio | Activity | % Change to Portfolio | Reported Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026 Q1 | 5,461,037 | 0.40 | Reduce 0.85% | <0.01 | $131.74 | $719,437,014 | SEC |
| 2025 Q4 | 5,508,042 | 0.42 | Reduce 0.87% | <0.01 | $141.83 | $781,205,597 | SEC |
| 2025 Q3 | 5,556,618 | 0.42 | Reduce 0.18% | <0.01 | $140.38 | $780,038,035 | SEC |
| 2025 Q2 | 5,566,814 | 0.39 | Add 0.58% | <0.01 | $125.69 | $699,692,852 | SEC |
| 2025 Q1 | 5,534,624 | 0.35 | Add 83.48% | 0.16 | $110.60 | $612,129,414 | SEC |
| 2024 Q4 | 3,016,425 | 0.24 | Add 134.23% | 0.14 | $136.50 | $411,742,013 | SEC |
| 2024 Q3 | 1,287,820 | 0.08 | Add 0.55% | <0.01 | $115.22 | $148,382,620 | SEC |
| 2024 Q2 | 1,280,820 | 0.11 | Add 1.23% | <0.01 | $137.67 | $176,330,489 | SEC |
| 2024 Q1 | 1,265,244 | 0.10 | Add 0.44% | <0.01 | $137.92 | $174,502,452 | SEC |
| 2023 Q4 | 1,259,744 | 0.11 | Add 489.76% | 0.09 | $131.76 | $165,983,869 | SEC |
| 2023 Q3 | 213,602 | 0.02 | Buy | 0.02 | $112.50 | $24,030,225 | SEC |